ALLENDALE, N.J.--(BUSINESS WIRE)--A research plan that is designed to determine the degree of effectiveness of an experimental non-drug therapy known as ImmunoModulation for the treatment of psoriasis as a primary indication and psoriatic arthritis as a secondary indication, will be filed with the Federal Food and Drug Administration in an expedited manner.
